Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00117091 | Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA) | PHASE3 | COMPLETED | - | — | — | - | - | Dec 24, 2007 | - | — |
| NCT00037700 | Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid Arthritis | PHASE2 | COMPLETED | - | — | — | May 1, 2001 | Dec 1, 2002 | Nov 26, 2009 | - | — |
| Name | Type | Description |
|---|---|---|
| Anakinra (Kineret®) | DRUG | - |
| anakinra | DRUG | - |
| pegsunercept | DRUG | - |
Inclusion Criteria: - Subjects diagnosed with RA as determined by American College of Rheumatology (ACR) criteria with a disease duration of at least 24 weeks prior to enrollment - Active RA at screening as defined by EITHER: (1) At least 6 swollen joints (using a 66 joint count) and at least 6 tend...